COMPANY RESEARCHNEORAL cyclosporine is a classic benchmark for oral cyclic peptides and microemulsion preconcentrates; it should not be assumed bioequivalent to Sandimmune.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
NEORAL cyclosporine is a classic benchmark for oral cyclic peptides and microemulsion preconcentrates; it should not be assumed bioequivalent to Sandimmune.
An original Phase 1 DKY709 abstract at AACR 2026 describes an oral IKZF2 molecular glue and reports human pharmacodynamic, PK, and preliminary efficacy data through 2024-09-05.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| cyclosporine / NEORAL | Cyclophilin / Calcineurin · Immunosuppression-related indications | Approved | Label reports systemic exposure and formulation differences |
| DKY709 | IKZF2 / Helios · See individual trial / indication; not individually confirmed in this review | Phase 1 | Human target degradation and preliminary safety / efficacy |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Monte Rosa announced that Novartis initiated a second Phase 2 study of the VAV1 molecular glue degrader MRT-6160, also called DDY391, in active moderate to severe psoriatic arthritis. The randomized, double-blind, placebo-controlled trial will assess efficacy, safety, tolerability, and dose response. The first patient visit triggers a $37.5 million milestone payment.
Unnatural Products licensed an undisclosed cardiovascular program to Novartis. Terms include up to $100 million in upfront and pre-IND payments, plus up to $1.7 billion in later milestones and royalties. The platform supports oral and injectable macrocycles; the announcement does not establish the specific program’s route or imply all contingent payments have been received.
Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.
Nurix announced updated Phase 1a/1b findings for its oral BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL. The ASH presentation will include patients previously exposed to covalent BTK inhibitors and data at the recommended Phase 2 dose of 600 mg once daily. The release describes durable activity without providing numerical response rates.
A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
